BYSI vs. HUMA, AMRN, PRTA, BNTC, HRTX, SNDL, VOR, AURA, ATXS, and AVTE
Should you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Humacyte (HUMA), Amarin (AMRN), Prothena (PRTA), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), SNDL (SNDL), Vor Biopharma (VOR), Aura Biosciences (AURA), Astria Therapeutics (ATXS), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.
BeyondSpring vs. Its Competitors
Humacyte (NASDAQ:HUMA) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.
In the previous week, Humacyte had 5 more articles in the media than BeyondSpring. MarketBeat recorded 7 mentions for Humacyte and 2 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.15 beat Humacyte's score of 0.53 indicating that BeyondSpring is being referred to more favorably in the news media.
Humacyte has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500.
Humacyte presently has a consensus target price of $11.71, indicating a potential upside of 413.78%. Given Humacyte's stronger consensus rating and higher possible upside, equities research analysts clearly believe Humacyte is more favorable than BeyondSpring.
BeyondSpring has higher revenue and earnings than Humacyte.
44.7% of Humacyte shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 5.1% of Humacyte shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Humacyte beats BeyondSpring on 8 of the 13 factors compared between the two stocks.
Get BeyondSpring News Delivered to You Automatically
Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BeyondSpring Competitors List
Related Companies and Tools
This page (NASDAQ:BYSI) was last updated on 7/15/2025 by MarketBeat.com Staff
Free BYSI Stock Alerts